Literature DB >> 20840471

Effects of systemic inhibition of Rho kinase on blood pressure and renal haemodynamics in diabetic rats.

R Komers1, T T Oyama, D R Beard, S Anderson.   

Abstract

BACKGROUND AND
PURPOSE: The RhoA/Rho associated kinases (ROCK) pathway has been implicated in the pathophysiology of diabetic nephropathy (DN). Early stages of diabetes are associated with renal haemodynamic changes, contributing to later development of DN. However, the role of RhoA/ROCK, known regulators of vascular tone, in this process has not been studied. EXPERIMENTAL APPROACH: Blood pressure (BP), glomerular filtration (GFR), effective renal plasma flow and filtration fraction (FF) in response to the ROCK inhibitors Y27632 (0.1 and 0.5 mg·kg(-1) ) and fasudil (0.3 and 1.5 mg·kg(-1) ) were examined in streptozotocin-diabetic rats and non-diabetic controls. KEY
RESULTS: Diabetic rats demonstrated baseline increases in GFR and FF. In contrast to similar decreases in BP in diabetic and control rats, renal vasodilator effects and a decrease in FF, following ROCK inhibition were observed only in diabetic rats. The vasodilator effects of Y27632 and a further decrease in FF, were also detected in diabetic rats pretreated with the angiotensin antagonist losartan. The effects of ROCK inhibitors in diabetic rats were modulated by prior protein kinase C (PKC)β inhibition with ruboxistaurin, which abolished their effects on FF. Consistent with the renal vasodilator effects, the ROCK inhibitors reduced phosphorylation of myosin light chain in diabetic kidneys. CONCLUSIONS AND IMPLICATIONS: The results indicate greater dependence of renal haemodynamics on RhoA/ROCK and beneficial haemodynamic effects of ROCK inhibitors in diabetes, which were additive to the effects of losartan. In this process, the RhoA/ROCK pathway operated downstream of or interacted with, PKCβ in some segments of the renal vascular tree.
© 2010 The Authors. British Journal of Pharmacology © 2010 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20840471      PMCID: PMC3012414          DOI: 10.1111/j.1476-5381.2010.01031.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  50 in total

Review 1.  RhoA and resistance artery remodeling.

Authors:  Gervaise Loirand; Malvyne Rolli-Derkinderen; Pierre Pacaud
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-03       Impact factor: 4.733

2.  Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats.

Authors:  D Koya; M R Jirousek; Y W Lin; H Ishii; K Kuboki; G L King
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

3.  Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury.

Authors:  Guang-Ping Sun; Masakazu Kohno; Peng Guo; Yukiko Nagai; Kayoko Miyata; Yu-Yan Fan; Shoji Kimura; Hideyasu Kiyomoto; Koji Ohmori; De-Tian Li; Youichi Abe; Akira Nishiyama
Journal:  J Am Soc Nephrol       Date:  2006-06-21       Impact factor: 10.121

Review 4.  Physiologic actions and molecular expression of the renin-angiotensin system in the diabetic rat.

Authors:  S Anderson
Journal:  Miner Electrolyte Metab       Date:  1998

5.  Altered endothelial nitric oxide synthase targeting and conformation and caveolin-1 expression in the diabetic kidney.

Authors:  Radko Komers; William E Schutzer; John F Reed; Jessie N Lindsley; Terry T Oyama; David C Buck; Scott L Mader; Sharon Anderson
Journal:  Diabetes       Date:  2006-06       Impact factor: 9.461

Review 6.  Protein kinase C activation and the development of diabetic complications.

Authors:  D Koya; G L King
Journal:  Diabetes       Date:  1998-06       Impact factor: 9.461

7.  Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension.

Authors:  M Uehata; T Ishizaki; H Satoh; T Ono; T Kawahara; T Morishita; H Tamakawa; K Yamagami; J Inui; M Maekawa; S Narumiya
Journal:  Nature       Date:  1997-10-30       Impact factor: 49.962

8.  M3 muscarinic acetylcholine receptors regulate cytoplasmic myosin by a process involving RhoA and requiring conventional protein kinase C isoforms.

Authors:  D Strassheim; L G May; K A Varker; H L Puhl; S H Phelps; R A Porter; R S Aronstam; J D Noti; C L Williams
Journal:  J Biol Chem       Date:  1999-06-25       Impact factor: 5.157

9.  Upregulation of small GTPase RhoA in the basilar artery from diabetic (mellitus) rats.

Authors:  L Miao; J W Calvert; J Tang; J H Zhang
Journal:  Life Sci       Date:  2002-07-26       Impact factor: 5.037

10.  Rho-kinase inhibition blunts renal vasoconstriction induced by distinct signaling pathways in vivo.

Authors:  Alessandro Cavarape; Nicole Endlich; Roberta Assaloni; Ettore Bartoli; Michael Steinhausen; Niranjan Parekh; Karlhans Endlich
Journal:  J Am Soc Nephrol       Date:  2003-01       Impact factor: 10.121

View more
  13 in total

1.  Myosin light chain kinase is involved in the mechanism of gastrointestinal dysfunction in diabetic rats.

Authors:  Wenchao Hu; Ping Feng
Journal:  Dig Dis Sci       Date:  2012-05       Impact factor: 3.199

2.  Blocking VEGF/Caveolin-1 signaling contributes to renal protection of fasudil in streptozotocin-induced diabetic rats.

Authors:  Jing Jin; Chao Peng; Su-zhen Wu; Hong-min Chen; Bai-fang Zhang
Journal:  Acta Pharmacol Sin       Date:  2015-05-04       Impact factor: 6.150

Review 3.  Rho kinase inhibition in diabetic kidney disease.

Authors:  Radko Komers
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

Review 4.  Biologically active isoquinoline alkaloids covering 2014-2018.

Authors:  Xiao-Fei Shang; Cheng-Jie Yang; Susan L Morris-Natschke; Jun-Cai Li; Xiao-Dan Yin; Ying-Qian Liu; Xiao Guo; Jing-Wen Peng; Masuo Goto; Ji-Yu Zhang; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2020-07-29       Impact factor: 12.944

Review 5.  Potential benefits of rho-kinase inhibition in arterial hypertension.

Authors:  Olaf Grisk
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

6.  Prevention of diabetes-induced arginase activation and vascular dysfunction by Rho kinase (ROCK) knockout.

Authors:  Lin Yao; Surabhi Chandra; Haroldo A Toque; Anil Bhatta; Modesto Rojas; Ruth B Caldwell; R William Caldwell
Journal:  Cardiovasc Res       Date:  2012-12-17       Impact factor: 10.787

Review 7.  Pathophysiology of the diabetic kidney.

Authors:  Volker Vallon; Radko Komers
Journal:  Compr Physiol       Date:  2011-07       Impact factor: 9.090

8.  Activated Rho kinase mediates diabetes-induced elevation of vascular arginase activation and contributes to impaired corpora cavernosa relaxation: possible involvement of p38 MAPK activation.

Authors:  Haroldo A Toque; Kenia P Nunes; Lin Yao; James K Liao; R Clinton Webb; Ruth B Caldwell; R William Caldwell
Journal:  J Sex Med       Date:  2013-04-08       Impact factor: 3.802

Review 9.  Druggable targets in the Rho pathway and their promise for therapeutic control of blood pressure.

Authors:  Rachel A Dee; Kevin D Mangum; Xue Bai; Christopher P Mack; Joan M Taylor
Journal:  Pharmacol Ther       Date:  2018-09-04       Impact factor: 12.310

10.  The ADF/Cofilin-Pathway and Actin Dynamics in Podocyte Injury.

Authors:  Beina Teng; Alexander Lukasz; Mario Schiffer
Journal:  Int J Cell Biol       Date:  2011-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.